Search by Drug Name or NDC

    NDC 00069-0502-30 XELJANZ 22 mg/1 Details

    XELJANZ 22 mg/1

    XELJANZ is a ORAL TABLET, FILM COATED, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TOFACITINIB CITRATE.

    Product Information

    NDC 00069-0502
    Product ID 0069-0502_b66d67c5-58ad-437e-a098-1e4a18d1104d
    Associated GPIs 66603065107550
    GCN Sequence Number 080628
    GCN Sequence Number Description tofacitinib citrate TAB ER 24H 22 MG ORAL
    HIC3 Z2Z
    HIC3 Description JANUS KINASE (JAK) INHIBITORS
    GCN 47546
    HICL Sequence Number 039768
    HICL Sequence Number Description TOFACITINIB CITRATE
    Brand/Generic Brand
    Proprietary Name XELJANZ
    Proprietary Name Suffix XR
    Non-Proprietary Name tofacitinib
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED, EXTENDED RELEASE
    Route ORAL
    Active Ingredient Strength 22
    Active Ingredient Units mg/1
    Substance Name TOFACITINIB CITRATE
    Labeler Name Pfizer Laboratories Div Pfizer Inc
    Pharmaceutical Class Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA208246
    Listing Certified Through 2024-12-31

    Package

    NDC 00069-0502-30 (00069050230)

    NDC Package Code 0069-0502-30
    Billing NDC 00069050230
    Package 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0502-30)
    Marketing Start Date 2020-01-21
    NDC Exclude Flag N
    Pricing Information N/A